Applied Therapeutics, Inc.
CIK:
0001697532
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017
Mailing Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017
Phone
212-220-9226
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
$86.69M
Total Assets
$71.98M
Total Liabilities
$79.40M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.